News
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2018
Net sales of DARZALEX in the first quarter of 2018 totaled USD 432 million Genmab will receive royalties on worldwide sales from Janssen Biotech, Inc.. Copenhagen, Denmark; April 17, 2018– Genmab A/S announced today that worldwide net sales of DARZALEX as reported by Johnson& Johnson were USD 432 million in the first quarter of 2018. Net sales were USD 264 million...
Net sales of DARZALEX in the first quarter of 2018 totaled USD 432 million Genmab will receive royalties on worldwide sales from Janssen Biotech, Inc.. Copenhagen, Denmark; April 17, 2018– Genmab A/S announced today that worldwide net sales of DARZALEX as reported by Johnson& Johnson were USD 432 million in the first quarter of 2018. Net sales were USD 264 million...